EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost Considerations for Rapid Start Implementation: Analysis from Seven Rapid Start Provider Sites

Pamela M Murnane, Starley B Shade, Monika Damle, Thomas Donohoe, Dawn Middleton, Sara Friedman, Tony Jimenez, Kendall Brooks, Lindsay Senter

AIDS and Behavior · 2026-08 · 30 (8) · 2442-2451

DOI: 10.1007/s10461-026-05069-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AIDS and Behavior, online erschienen am 28.04.2026. Verfasst von Pamela M Murnane und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA. Pamela.murnane@ucsf.edu. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents, Health Care Costs. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HRSA HHS, Health Resources and Services Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antiretroviral treatment (ART) initiation within days of HIV diagnosis, also known as “Rapid Start”, improves linkage to care, virologic suppression and retention in care. However, data on the costs of Rapid Start implementation in the United States are limited. We aimed to estimate the costs and cost-effectiveness of Rapid Start among seven geographically diverse Ryan White-funded programs with broad variability in populations served and services offered. Each site estimated the costs of ART initiation services, management, and Rapid Start planning activities in three 12-month periods: pre-, initial, and sustained implementation. We estimated quality-adjusted life years (QALY) saved, incremental costs per-person and incremental cost per QALY saved during implementation. We considered an intervention cost-effective if it cost

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAnti-HIV AgentsHealth Care CostsHumansCost-Benefit AnalysisCost-Effectiveness AnalysisUnited StatesQuality-Adjusted Life Years

Stichwörter der Autor:innen

Costs and cost analysisHIV infectionsTreatment initiation

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA. Pamela.murnane@ucsf.edu.
  • Institute for Global Health Sciences, University of California, San Francisco, San Francisco, CA, USA. Pamela.murnane@ucsf.edu.
  • Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
  • Institute for Global Health Sciences, University of California, San Francisco, San Francisco, CA, USA.
  • Cicatelli Associates, Inc, New York, NY, USA.
  • Department of Family Medicine, David Geffen School of Medicine at UCLA, 550 16th Street, Los Angeles, CA, 94158, USA.

Förderung

  • HRSA HHS
  • Health Resources and Services Administration

Zitieren

APA

Murnane, P. M., Shade, S. B., Damle, M., Donohoe, T., Middleton, D., Friedman, S., Jimenez, T., Brooks, K., & Senter, L. (2026). Cost Considerations for Rapid Start Implementation: Analysis from Seven Rapid Start Provider Sites. AIDS and Behavior, 30(8), 2442-2451. https://doi.org/10.1007/s10461-026-05069-7

Vancouver

Murnane PM, Shade SB, Damle M, Donohoe T, Middleton D, Friedman S, et al. Cost Considerations for Rapid Start Implementation: Analysis from Seven Rapid Start Provider Sites. AIDS and Behavior. 2026;30(8):2442-2451. doi:10.1007/s10461-026-05069-7

BibTeX
@article{Murnane2026,
  author = {Murnane, Pamela M and Shade, Starley B and Damle, Monika and Donohoe, Thomas and Middleton, Dawn and Friedman, Sara and Jimenez, Tony and Brooks, Kendall and Senter, Lindsay},
  title = {Cost Considerations for Rapid Start Implementation: Analysis from Seven Rapid Start Provider Sites},
  journal = {AIDS and Behavior},
  year = {2026},
  volume = {30},
  number = {8},
  pages = {2442--2451},
  doi = {10.1007/s10461-026-05069-7}
}
Kostenlos starten →